Standout Papers

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with ad... 2009 2026 2014 2020 570
  1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial (2009)
    Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology

Immediate Impact

2 from Science/Nature 93 standout
Sub-graph 1 of 16

Citing Papers

Oesophageal cancer
2024 Standout
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
1 intermediate paper

Works of T. Suarez being referenced

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009 Standout

Author Peers

Author Last Decade Papers Cites
T. Suarez 584 408 25 504 8 926
J.E. de Vries 311 362 15 478 23 1.0k
Axel Hittelet 240 347 7 560 18 827
P Klementschitsch 168 132 12 615 10 1.1k
Claude Desaive 297 523 38 667 13 921
Flávia Ferretti Santiago 688 358 22 279 5 760
M. G. Sarr 254 566 18 552 11 790
M.J. Cornelius 135 148 7 186 9 772
Richard Whitehead 133 124 50 687 12 1.1k
Charles J. Yeo 538 918 15 866 12 1.1k
Karim Aghcheli 245 276 3 566 13 1.0k

All Works

Loading papers...

Rankless by CCL
2026